What Is Urocortin? Definition and What Research Reports

Definition

Urocortin is the name given to a small group of peptide hormones and neuropeptides that belong to the corticotropin-releasing factor (CRF, also written CRH) family. Like CRF itself, urocortins are short chains of amino acids — roughly 38 to 43 residues, depending on the form — that are produced in the brain and in several peripheral tissues, and that signal by binding CRF receptors on target cells. The term is used both for the original peptide discovered in the 1990s, urocortin 1, and as a collective label for the wider set that includes urocortin 2 and urocortin 3. In the published literature the word rarely appears alone; papers usually specify which member is being studied, because the three differ in where they are expressed, which receptor they prefer, and what experimental readouts they change.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions. Nothing here describes how any substance should be used.

What Class of Molecule It Is, and Where It Comes From

Urocortins are endogenous peptides — that is, the body makes them itself — rather than synthetic research chemicals invented in a laboratory, although synthetic and modified versions have been produced for experimental work. They are encoded by their own genes, translated as larger precursor proteins, and cleaved to the mature peptide. They are structurally related to CRF and to non-mammalian peptides such as urotensin and sauvagine, which is where the name originates.

Functionally, urocortins are classed as ligands at two G-protein-coupled receptors, CRF receptor type 1 (CRF1) and type 2 (CRF2). A comprehensive review of urocortin in the central nervous system described urocortin 1 as binding both CRF1 and CRF2, while urocortin 2 and urocortin 3 were characterised as selective for CRF2 (PMID 18078706). That receptor selectivity is the main reason the three peptides are studied separately rather than interchangeably.

The three forms at a glance

How the Term Is Used in Peptide Research

In the peptide literature, "urocortin" turns up in three distinct contexts, and readers encountering the word benefit from knowing which one a given paper means.

• As a marker for a population of neurons. Researchers frequently use urocortin expression to identify and manipulate specific cell groups — for example, urocortin-1 neurons of the Edinger-Westphal nucleus, or urocortin-3-expressing neurons in the hypothalamus or spinal cord — rather than studying the peptide as an administered substance.
• As an endogenous signal measured in tissue or blood. Studies quantify urocortin messenger RNA or protein in a tissue and compare groups, which is the approach used in work on stress and on gynaecological tissue.
• As an experimental agonist. Synthetic urocortin peptides, or gene-transfer constructs that make cells produce them, have been given to animals and, in a small number of studies, to human participants, in order to observe physiological responses at CRF receptors.

A 2006 peptide-chemistry paper illustrates the third use: researchers described modifications of the human urocortin 2 peptide intended to improve its pharmacological properties (PMID 16476507). Work of this kind is why analogue names and sequence variants appear alongside the parent peptide in later literature.

What the Published Literature Reports

Brain, stress and behaviour

A 2025 study reported that urocortin-1 neurons of the Edinger-Westphal nucleus regulated consumption and affect (PMID 40512623). Separately, researchers reported that hypothalamic perifornical urocortin-3 neurons modulated defensive responses to a potential threat stimulus (PMID 33385113). A rat study examined the relationship between stress exposure and urocortin, and the authors framed their findings as linking stress with urocortin (PMID 38046515). The broader review of urocortin and the brain summarised the peptide's distribution and its proposed roles in central CRF signalling (PMID 18078706).

Cardiovascular and metabolic research

In a clinical pharmacology study, researchers examined the cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure (PMID 27275843). A review article asked whether urocortin 2 has a protective effect in hypertension and surveyed the supporting and conflicting evidence (PMID 37245228). On the metabolic side, a preclinical report described urocortin 2 gene transfer as improving glycemic control and reducing retinopathy and mortality in a murine model of insulin deficiency (PMID 31970200). These are animal-model and patient-study findings reported by the investigators, not statements about outcomes in any individual.

Peripheral tissues and disease-association work

A systematic review collected studies of urocortin expression in endometriosis and evaluated whether expression differed between affected and unaffected tissue (PMID 30644237). In cell-culture work, researchers reported that urocortin stimulated ERK1/2 phosphorylation and proliferation while reducing ATP production in MCF7 breast cancer cells (PMID 35219718). Sensory research has also implicated the family: a 2025 paper reported that spinal lumbar urocortin-3-expressing neurons were associated with both scratching and compound 48/80-induced sensations (PMID 39432740).

Reported Effects and Adverse Events: What Studies Report

Because urocortins act at receptors present in the brain, heart, gut, skin and endocrine tissue, the published record includes physiological responses that would not be considered desirable in every context. The following are drawn only from the cited papers.

• Body-temperature responses. A 2025 rat study characterised an aging-associated increase in urocortin 2-induced hyperthermia in middle-aged male Wistar rats, and reported that treadmill training or caloric restriction delayed that increase (PMID 41408446).
• Cell proliferation in a cancer cell line. Researchers reported that urocortin stimulated proliferation of MCF7 breast cancer cells in culture alongside reduced ATP production (PMID 35219718).
• Itch-related sensory signalling. Spinal urocortin-3-expressing neurons were associated with scratching behaviour in the study cited above (PMID 39432740).
• Haemodynamic effects in patients. Cardiovascular responses to urocortin 2 and urocortin 3 were the primary object of measurement in chronic heart failure patients (PMID 27275843), and any peptide that changes haemodynamics is studied under monitored clinical conditions.

Status and Limitations

Urocortin peptides are not approved medicines; the human work that exists sits in the investigational and clinical-pharmacology space, such as the heart failure study described above (PMID 27275843). Most of the evidence base is preclinical — rodent, cell-culture and gene-transfer models — and the review literature itself raises open questions rather than settled conclusions, as the title of the hypertension review indicates (PMID 37245228).

Three limitations recur across this body of work. First, findings in one urocortin do not transfer automatically to another, because receptor selectivity differs (PMID 18078706). Second, studies that manipulate urocortin-expressing neurons describe circuit function, not the effect of an administered peptide. Third, gene-transfer results in mice, such as those reported in murine insulin deficiency (PMID 31970200), reflect a delivery method quite different from peptide administration and are not interchangeable with it.

References

• Urocortin and the brain (Progress in Neurobiology, 2008)
• Edinger-Westphal Urocortin-1 neurons regulate consumption and affect (Cell Reports, 2025)
• Hypothalamic perifornical Urocortin-3 neurons modulate defensive responses to a potential threat stimulus (iScience, 2021)
• Linking stress with urocortin in rats (Bioinformation, 2023)
• Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure (British Journal of Clinical Pharmacology, 2016)
• Urocortin 2 - a protective effect in hypertension? (Journal of Physiology and Pharmacology, 2023)
• Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency (Molecular Therapy: Methods & Clinical Development, 2020)
• Urocortin Expression in Endometriosis: A Systematic Review (International Journal of Fertility & Sterility, 2019)
• Urocortin stimulates ERK1/2 phosphorylation and proliferation but reduces ATP production of MCF7 breast cancer cells (Molecular and Cellular Endocrinology, 2022)
• Spinal lumbar Urocortin 3-expressing neurons are associated with both scratching and Compound 48/80-induced sensations (Pain, 2025)
• Treadmill training or caloric restriction delays aging-associated increase in urocortin 2-induced hyperthermia in middle-aged male Wistar rats (Scientific Reports, 2025)
• Modifications of the human urocortin 2 peptide that improve pharmacological properties (Peptides, 2006)